CEO Richard Francis reflects on Teva’s return to growth during his tenure,
and what’s next for the drugmaker in its quest to recapture the heights of old.
Related Posts
FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk
Navigating Distrust: Pharma in the Age of Social Media